Non-publication of clinical trial results has been recognized as a serious scientific and ethical problem. Underreporting frustrates evaluation of a drug’s utility and safety, and fails to redeem the sacrifice of trial participants. Thus far, policy measures to counteract non-publication have focused on trials of interventions used in practice. However, 9/10 interventions entering clinical testing… Continue reading Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials
Tag: bioethics
The Landscape of Early Phase Research
As Jonathan is fond of saying: Drugs are poisons. It is only through an arduous process of testing and refinement that a drug is eventually transformed into a therapy. Much of this transformative work falls to the early phases of clinical testing. In early phase studies, researchers are looking to identify the optimal values for the various… Continue reading The Landscape of Early Phase Research
The Literature Isn’t Just Biased, It’s Also Late to the Party
Animal studies of drug efficacy are an important resource for designing and performing clinical trials. They provide evidence of a drug’s potential clinical utility, inform the design of trials, and establish the ethical basis for testing drugs in human. Several recent studies suggest that many preclinical investigations are withheld from publication. Such nonreporting likely reflects… Continue reading The Literature Isn’t Just Biased, It’s Also Late to the Party
Teaching Kills Blogging: Somewhat Recent Developments…
Dear Faithful Readers: Teaching has cut my blogging to a trickle, though the teaching has now begun to taper off. My silence is not for want of major developments in the last two months. Among a few highlights: • Obama picks members for his Bioethics advisory panel: White house recently announced membership of its “Presidential… Continue reading Teaching Kills Blogging: Somewhat Recent Developments…